A Phase II, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy, Followed by Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab, in Borderline Resectable Stage III NSCLC (ACCESS)
Latest Information Update: 06 Jun 2025
At a glance
- Drugs Durvalumab (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ACCESS
Most Recent Events
- 06 Jun 2025 New trial record